Plunkett Research Online: Epizyme Inc

EPIZYME INC (EPZM:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

Epizyme, Inc. is a biopharmaceutical company offering treatment for people with cancer and other serious diseases via discovery, development and commercialization of novel epigenetic medicines. The U.S. Food and Drug Administration (FDA) granted accelerated approval of Epizyme’s TAZVERIK (tazemetos.....



Epizyme Inc
Ticker: EPZM
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 617-229-5872
Fax:
Address: 400 Technology Square
4th Floor
Cambridge, MA 02139 United States

Map
Types Of Business
Industry Ranks

Industry NAICS code:

Biopharmaceuticals
Biopharmaceuticals
Clinical Testing
Pharmaceutical Development
Pharmaceutical Commercialization
Contacts Description

Robert Bazemore CEO/President/Director
Matthew Ros CFO/Other Executive Officer
See More
Epizyme, Inc. is a biopharmaceutical company offering treatment for people with cancer and other serious diseases via discovery, development and commercialization of novel epigenetic medicines. The U.S. Food and Drug Administration (FDA) granted accelerated approval of Epizyme’s TAZVERIK (tazemetos.....See More See More

Auditor: EY
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2020 2019 2018 2017 2016 2015
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
TAZVERIK
Tazemetostat
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: